Solid Neoplasm Clinical Trial
Official title:
Pilot Study to Evaluate the Feasibility of Measuring (a) Intratumoral Pressures Using a Novel Piezo- Resistive Semiconductor Catheter and (b) Intratumoral Stiffness Using Shear Wave Elastography With Ultrasound
Verified date | May 2024 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial studies how well a Millar Mikro-tip catheter and shear wave elastography measure pressure and stiffness inside tumors among patients with solid tumors undergoing an ultrasound-guided biopsy. A Millar Mikro-tip catheter measures the pressure inside the tumor. Shear wave elastography is similar to an ultrasound and uses sound waves to vibrate the tissue in order to study tissue stiffness. These measurements may help doctors learn if pressure and stiffness are related to intratumoral fibrosis (the thickening and scarring of connective tissue).
Status | Active, not recruiting |
Enrollment | 27 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients who are scheduled for at least one biopsy (diagnostic or research) for solid organ tumors (excluding bone) at MD Anderson. - Patients who are able to understand and give consent to participation in the study. Exclusion Criteria: - Tumor size < 1.5 cm or > 5 cm in size on pre-procedural imaging for 1st assessment and < 1 cm for 2nd assessment - Pregnant women (these patients will be tested for pregnancy before they are scheduled for a diagnostic or research biopsy per inclusion criteria #1). - Tumors involving bone. |
Country | Name | City | State |
---|---|---|---|
United States | M D Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change in Tumor pressure | Measured by Millar Microcath (Millar Mikro-Tip Pressure Catheter). Tumor pressure and its change will be summarized using mean, standard deviation, and range by time point. | Up to 30 days | |
Primary | The change in Tumor stiffness | Measured by General Electric LOGIQ Shear Wave Elastography. Tumor stiffness and its change will be summarized using mean, standard deviation, and range by time point. | Up to 30 days | |
Secondary | Tumor pressure | As a secondary endpoint, the relationship of tumor pressure with tumor fibrosis will be assessed for each patient. An ordinary least squares regression will be fit to the data to investigate the potential relationship between tumor stiffness, pressure, and fibrosis. | Up to 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02540876 -
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
|
Phase 1 | |
Suspended |
NCT04060849 -
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
|
Phase 1 | |
Active, not recruiting |
NCT03834961 -
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
|
Phase 2 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01017640 -
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
Completed |
NCT03775616 -
Financial Navigation Program Intervention in Supporting Patients With Solid Tumors and Their Caregivers
|
N/A | |
Active, not recruiting |
NCT03098277 -
Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy
|
N/A | |
Completed |
NCT00503854 -
Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
|
||
Terminated |
NCT02414724 -
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT02876068 -
Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT02142803 -
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00085553 -
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02867592 -
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
|
Phase 2 | |
Recruiting |
NCT03023202 -
UWCCC Molecular Tumor Board Registry
|
||
Active, not recruiting |
NCT02706366 -
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT01552356 -
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT02567396 -
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
|
Phase 1 | |
Completed |
NCT02360215 -
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
|
Phase 3 | |
Withdrawn |
NCT03804255 -
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
|